Dyadic
DYAI1.1101.77% ( -0.020 )
Dyadic (DYAI)
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in...
- Open
- 1.120
- High
- 1.270
- Low
- 1.060
- Prev. Close
- 1.130
- Volume
- 310.50K
- Turnover
- 348.80K
- Avg Price
- 1.123
- Bid/Ask Ratio
- --
- Amplitude
- 18.58%
- 52wk High
- 1.600
- Volume Ratio
- 1.03
- Turnover Ratio
- 0.96%
Dyadic Analyst Rating
View MoreForecast & Rating
May 21, 2026Price forecast
$6.00440.54%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 24 at 04:12 PM
Francisco Trust trustee Thomas Emalfarb sells 95,392 Dyadic International common shares worth $124,823.82
- StockTitan · Jul 23 at 10:30 PM
Dyadic Announces Continued Listing on the Nasdaq Capital Market | DYAI Stock News
- rttnews · Jul 21 at 10:25 PM
Top Biotech Gainers: WGRX Rebrands, PVLA Nears FDA Milestone, ASBP On Track For NDA Filing
- benzinga_article · Jul 21 at 12:05 PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Unusual Whales · Jul 16 at 07:00 AM
Dyadic grows bio-industrial pipeline with innovative enzyme program, boosting its offerings in industrial sector.
- rttnews · Jul 14 at 10:18 PM
Top Biotech Gainers: NXTC Soars On Merger Deal, BMGL Moves Past Nasdaq Woes, OTLK Awaits FDA Verdict
